Myelodysplastic Syndromes

Why trials studying Myelodysplastic Syndromes stopped, in this sample of ClinicalTrials.gov.

41 stopped trials with a clear reason; 88% ended for non-scientific reasons.

Trials

• A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
  NCT07681440 · TERMINATED · slow accrual
  “Insufficient enrollment”
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
  NCT05895201 · WITHDRAWN · logistics pi
  “PI has left IU with no plan to initiate study at IU”
• Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
  NCT05246384 · WITHDRAWN · funding business
  “Change in development plan”
• A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
  NCT05607199 · TERMINATED · slow accrual
  “Patient recruitment problems.”
• ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
  NCT05358808 · TERMINATED · slow accrual
  “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”
• A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
  NCT05168202 · TERMINATED · funding business
  “Business objectives have changed”
• Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
  NCT05263271 · TERMINATED · funding business
  “Adjusted the product development strategy.”
• Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome
  NCT03643042 · TERMINATED · slow accrual
  “The SMD SEUIL TRANSFU study was stopped prematurely because we encountered enrolment difficulties and new treatments are available on the market for patients with RARS or SFR3B1 mutation (Luspatercept).”
• Thrombosomes® in Bleeding Thrombocytopenic Patients Study
  NCT04631211 · TERMINATED · funding business
  “This study was terminated due to loss of funding for this indication from the Biomedical Advanced Research and Development Authority (BARDA) in November 2022.”
• SNS-301 Monotherapy in High Risk MDS and CMML
  NCT04217720 · WITHDRAWN · funding business
  “Sponsor decision”
• Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
  NCT04296214 · WITHDRAWN · slow accrual
  “Poor recruitment”
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
  NCT03735446 · TERMINATED · funding business
  “Sponsor Decision”
• A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
  NCT04331483 · WITHDRAWN · other
  “modification of the intervention before patient's enrollment, new protocol submitted”
• Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)
  NCT03016130 · TERMINATED · safety
  “Interim analysis determined that study reached a safety stopping rule”
• Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
  NCT02929498 · TERMINATED · safety
  “The risk benefit in the study population does not favor continuation of the study”
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
  NCT02564536 · WITHDRAWN · funding business
  “Lack of funding following full FDA clinical hold”
• Nivolumab With Chemotherapy in Refractory MDS
  NCT03259516 · TERMINATED · slow accrual
  “Slow recruitment rate”
• Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
  NCT02928419 · TERMINATED · slow accrual
  “"the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"”
• Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)
  NCT02038816 · TERMINATED · slow accrual
  “accrual too slow, insufficient patients”
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
  NCT01908387 · TERMINATED · slow accrual
  “Due to Slow Accrual study was terminated.”
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
  NCT01892644 · WITHDRAWN · slow accrual
  “Failure to recruit patients with hemochromatosis to the Deferasirox arm”
• Exjade-Early-Trial
  NCT01058369 · TERMINATED · slow accrual
  “Insufficient patient recruitment (only 2 patients)”
• Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
  NCT01077440 · TERMINATED · logistics pi
  “PI leaving institution”
• Pilot Study of Unrelated Cord Blood Transplantation
  NCT00916045 · TERMINATED · slow accrual
  “Recruitment issues”
• Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
  NCT00923234 · TERMINATED · slow accrual
  “The primary objective has already been answered with the number of recruited patients.”
• A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
  NCT00750334 · TERMINATED · funding business
  “Terminated to focus on comparable trial, CLOMDS02507”
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
  NCT00555048 · TERMINATED · slow accrual
  “Low accrual”
• A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
  NCT00569179 · TERMINATED · slow accrual
  “Slow accrual”
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
  NCT00480987 · TERMINATED · funding business
  “Lack of support.”
• Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes
  NCT00503880 · TERMINATED · funding business
  “Genzyme discontinued Funding”
• Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
  NCT00234000 · TERMINATED · slow accrual
  “The study was closed due to poor enrollment”
• Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
  NCT00356928 · TERMINATED · slow accrual
  “Poor accrual”
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
  NCT00827099 · TERMINATED · safety
  “Unacceptable morbidity \& mortality”
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
  NCT00608517 · TERMINATED · slow accrual
  “slow accrual”
• G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
  NCT00253552 · TERMINATED · logistics pi
  “Terminated at request of PI as study was outdated.”
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
  NCT00255684 · TERMINATED · slow accrual
  “low accrual”
• Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
  NCT00062231 · TERMINATED · slow accrual
  “low accrual”
• Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
  NCT00301912 · WITHDRAWN · slow accrual
  “Withdrawn because study never opened to accrual”
• Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
  NCT00069992 · TERMINATED · slow accrual
  “Closed due to competing protocols”
• 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
  NCT00004058 · TERMINATED · other
  “At this time it is felt that we will not gain further information from an additional patients.”
• A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
  NCT00446602 · WITHDRAWN · funding business
  “Due to company decision to focus resources on a larger, controlled study in this patient population.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.